Nilotinib nanoparticle formulation (Xspray Pharma)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameNilotinib nanoparticle formulation (Xspray Pharma)
Drug Alias NameHyNap-NiloRightSize nilotinibXS-003
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomIndia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesXspray Pharma
China Registration ClassN/A

Develop Information

Inactive CompaniesXspray Microparticles Ab
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A